Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome

Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome

Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has been shown to affect stem cells responsible for bl...

Full description

Bibliographic Details
Main Authors: Weiss, Glen J., Tibes, Raoul, Blaydorn, Lisa, Jameson, Gayle, Downhour, Molly, White, Erica, Caro, Ivor, Von Hoff, Daniel D.
Format: Online
Language:English
Published: PAGEPress Publications 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211514/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211514/

Similar Items